ABSTRACT
Introduction Hospitalisations relating to acute respiratory deteriorations (ARD) in Interstitial Lung Disease (ILD) have poor outcomes. Factors predicting adverse outcomes are not fully understood and data addressing the use of illness severity scores in prognostication are limited.
Objective To investigate the use of CURB-65 and NEWS-2 severity scores in the prediction of mortality following ARD-ILD hospitalisation, using prospective methodology and to validate previously determined cut-offs, derived from a retrospective study cohort.
Methods A dual-centre prospective observational cohort study of all adults (≥18y) hospitalised with ARD-ILD in Bristol, UK (n=179). Gender-Age-Physiology (GAP), CURB-65 and NEWS-2 scores were calculated for each eligible admission.
Receiver operating characteristics (ROC) curve analysis was used to quantify the strength of discrimination for NEWS-2 and CURB-65 scores. Univariable and multivariable logistic regression analyses were performed to explore the relationship between baseline severity scores and mortality.
Results GAP showed some merit at predicting 30-day mortality (AUC=0.64, P=0.015); whereas CURB-65 showed modest predictive value for in-hospital (AUC=0.72, P<0.001) and 90-day mortality (AUC=0.67, P<0.001). NEWS-2 showed higher predictive value for in-hospital (AUC=0.80, P<0.001) and 90-day mortality (AUC=0.75, P<0.001), with an optimal derived cut-off ≥6.5 found to be sensitive and specific for predicting in-hospital (83% and 63%) and 90-day (73% and 72%) mortality. In exploratory analyses, GAP score addition improved the predictive ability of NEWS-2 against 30-day mortality and CURB-65 across all time-periods.
Conclusion NEWS-2 has good discriminatory value for predicting in-hospital mortality and moderate discriminatory value for predicting 90-day mortality. The optimal NEWS-2 cut-off value determined was the same as in a previous retrospective cohort, confirming the NEWS-2 score shows promise in predicting mortality following ARD-ILD hospitalisation.
Competing Interest Statement
CH is Principal Investigator of the AvonCAP study, which is an investigator-led University of Bristol study funded by Pfizer, Inc, and is currently a member of the BTS Pulmonary Infection Specialty Advisory Group (SAG). AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts (WHO ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator for this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates The other authors declare no competing interests.
Clinical Protocols
https://www.isrctn.com/ISRCTN17354061
Funding Statement
The AvonCAP study is an investigator-led University of Bristol sponsored study which was designed and implemented collaboratively with Pfizer, Inc. which also funded the study. For the current manuscript, Pfizer staff did not play any part in data collection, analysis plan, data analysis or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Authority East of England Ethics Committee, including use of Section 251 of the 2006 NHS Act approved by the Confidentiality Advisory Group (REC:20/EE/0157, ISRCTN:17354061).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript updated following peer review
Data Availability
The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality regulations. Therefore, individual participant data and a data dictionary are not available to other researchers.
ABBERVIATIONS
- 6MWT
- c6-minute walk test
- aLRTD
- acute lower respiratory tract disease
- AE
- acute exacerbation
- ARD
- Acute respiratory deterioration
- AUROC
- Area Under the Receiver Operating Curve
- CRP
- C-reactive protein
- CI
- confidence interval
- CCI
- Charlson comorbidity index
- CPFE
- combined pulmonary fibrosis and emphysema (IPF with emphysema)
- CT
- computerized tomography (CT) scan
- CTD
- connective tissue disease
- CXR
- Chest x-ray (i.e. chest radiograph)
- GAP
- Gender-Age-Physiology
- FVC
- Forced vital capacity
- HFNO
- high flow nasal oxygen
- HR
- hazard ratio
- ILD
- Interstitial lung disease
- IMV
- invasive mechanical ventilation
- IPF
- Idiopathic pulmonary fibrosis
- IQR
- interquartile range;
- LFTs
- lung function tests
- LOS
- length of stay
- MDT
- multidisciplinary team
- NEWS-2
- National Early Warning Score-2
- NIV
- non-invasive ventilation
- NSIP
- non-specific interstitial pneumonia
- NP-LRTI
- non-pneumonic lower respiratory tract infection
- OR
- odds ratio
- PFTs
- pulmonary function tests
- PSI
- pneumonia severity index
- qSOFA
- Sequential Organ Failure Assessment
- ROC
- Receiver Operating Curve
- TLCO
- transfer capacity of the lung, for the uptake of carbon monoxide
